APPROVED_FOR_MARKETINGNCT02496689
Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)
Studying Hypophosphatasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Principal Investigator
- Andrew Denker, MD, PhDMedical Monitor
- Intervention
- asfotase alfa(biological)
- Eligibility
- All sexes
Study locations (5)
- Colorado Center for Bone Research, Lakewood, Colorado, United States
- Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Hôpital Bicêtre, Le Kremlin-Bicêtre, France
- Hôpital Necker - Enfants Malades, Paris, France
- Hôpital des Enfants, Toulouse, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02496689 on ClinicalTrials.govOther trials for Hypophosphatasia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07179640A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1Alesta Therapeutics
- ACTIVE NOT RECRUITINGPHASE3NCT06079359Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPPAlexion Pharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE3NCT06079372Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase AlfaAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT05234567A Prospective Sub-Study of the Global Hypophosphatasia RegistryAlexion Pharmaceuticals, Inc.
- RECRUITINGNCT05062629United States Hypophosphatasia Molecular Research CenterChildren's Mercy Hospital Kansas City
- ENROLLING BY INVITATIONNCT02306720Registry of Patients With HypophosphatasiaAlexion Pharmaceuticals, Inc.